NOV INC (NOV)
US62955J1034 - Common Stock
15.49 -0.32 (-2.02%)
After market: 15.62 +0.13 (+0.84%)
Fundamental Rating
Taking everything into account, NOV scores 4 out of 10 in our fundamental rating. NOV was compared to 93 industry peers in the Energy Equipment & Services industry. NOV scores bad on very profitability, while its financial health is fine. Not spectacular, but in line with the averages. NOV is not priced too expensively while it is growing strongly. Keep and eye on this one!
Profitability
Profitability Rating
The Piotroski-F score of NOV is 5.00. This is a neutral score and indicates average health and profitability for NOV.
NOV has a Return On Assets of 3.25%. This is below the industry average of 6.20%.
NOV's Return On Equity of 6.31% is worse than the rest of the industry. The industry average Return On Equity is 12.14%.
NOV's Profit Margin of 4.33% is worse than the rest of the industry. The industry average Profit Margin is 5.68%.
VS Industry
ROA (3.25%) VS Industry: 30% outperformed.
0.09
27.38
ROE (6.31%) VS Industry: 25% outperformed.
0.13
350.47
Profit Margin (4.33%) VS Industry: 40% outperformed.
0.16
114.10
Valuation
Valuation Rating
The Forward Price/Earnings Ratio of 9.37 indicates a rather cheap valuation of NOV.
NOV's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
With a Price/Earnings Ratio of 17.60, NOV is valued on the expensive side.
When comparing the current price to the book value of NOV, we can conclude it is valued correctly. It is trading at 1.16 times its book value.
When comparing the price book ratio of NOV to the average industry price book ratio of 1.22, NOV is valued in line with its industry peers.
Compared to an average industry Price/Earning Ratio of 10.60, NOV is valued slightly more expensive.
When comparing the Enterprise Value to EBITDA ratio of NOV to the average industry ratio of 5.46, NOV is valued more expensive than its industry peers.
VS Industry
Price/Earnings (17.6) VS Industry: 29% outperformed.
413.25
0.90
Price/Book (1.16) VS Industry: 51% outperformed.
117.92
0.18
Enterprise Value/ EBITDA (10.38) VS Industry: 22% outperformed.
116.06
1.86
Growth
Growth Rating
The Earnings Per Share has grown by an impressive 466.67% over the past year.
NOV shows a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 23.78% yearly.
The Earnings Per Share is expected to grow by 32.81% on average over the next 5 years. This is a very strong growth
When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
NOV shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.39%.
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.
Measured over the past 5 years, NOV shows a decrease in Revenue. The Revenue has been decreasing by -0.18% on average per year.
Based on estimates for the next 5 years, NOV will show a small growth in Revenue. The Revenue will grow by 8.52% on average per year.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | 23.78% | 466.67% | 118.16% | 73.36% | 51.72% | 32.81% |
| Revenue | -0.18% | -5.14% | 31.39% | 16.55% | 13.37% | 10.27% | 8.52% |
Health
Health Rating
NOV has a Current Ratio of 2.35. This indicates that NOV is financially healthy and has no problem in meeting its short term obligations.
When comparing the Current Ratio to an average industry Current Ratio of 1.93, NOV is better placed than the average industry peer to meet its short term obligations.
NOV has a Quick Ratio of 1.47. This is a normal value and indicates that NOV is financially healthy and should not expect problems in meeting its short term obligations.
The Quick Ratio is in line with the industry averages, which is at 1.51.
The Debt to Equity ratio of NOV is in line with the industry averages.
NOV has a Altman-Z score comparable to the industry average, which is at 1.76.
NOV has a Piotroski-F score of 5.00. This indicates an average health and profitability for NOV.
NOV has an Altman-Z score of 1.74. This is a bad value and indicates that NOV is not financially healthy and even has some risk of bankruptcy.
VS Industry
Debt/Equity (0.37) VS Industry: 50% outperformed.
16.18
0.00
Quick Ratio (1.47) VS Industry: 47% outperformed.
0.18
8.35
Current Ratio (2.35) VS Industry: 67% outperformed.
0.18
9.02
Altman-Z (1.74) VS Industry: 48% outperformed.
-7.09
10.89
Dividend
Dividend Rating
NOV pays out 23.56% of its income as dividend. This is a sustainable payout ratio.
NOV has been paying a dividend for at least 10 years, so it has a reliable track record.
With a Yearly Dividend Yield of 1.35%, NOV has a reasonable but not impressive dividend return.
In the last 3 months the price of NOV has falen by -23.32%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
Compared to an average industry Dividend Yield of 2.92, NOV's dividend is way lower than its industry peers. On top of this 84% of the companies listed in the same industry pay a better dividend than NOV!
With a Dividend Yield of 1.35, NOV pays less dividend than the S&P500 average, which is at 2.71.
The dividend of NOV decreases each year by -0.17%.
VS Industry
Dividend Yield (1.35%) VS Industry: 16% outperformed.
0.17
11.20
NOV INC
NYSE:NOV (6/5/2023, 7:24:51 PM)
After market: 15.62 +0.13 (+0.84%)15.49
-0.32 (-2.02%)
Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryEnergy Equipment & Services
Earnings (Last)04-26 2023-04-26/amc
Earnings (Next)07-25 2023-07-25/amc
Inst Owners92.57%
Inst Owner Change-0.37%
Ins Owners0.8%
Ins Owner Change12.09%
Market Cap6.10B
Analysts77.14
Price Target25.81 (66.62%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.35% |
Dividend Growth(5Y)-0.17%
DP23.56%
Div Incr Years1
Div Non Decr Years2
Ex-Date06-15 2023-06-15 (0.05)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.28%
Min EPS beat(2)9.14%
Max EPS beat(2)43.42%
EPS beat(4)3
Avg EPS beat(4)116.76%
Min EPS beat(4)-51.76%
Max EPS beat(4)466.21%
Revenue beat(2)1
Avg Revenue beat(2)2.1%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)5.02%
Revenue beat(4)3
Avg Revenue beat(4)2.94%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)5.02%
PT rev (1m)-2.86%
PT rev (3m)-3.7%
EPS NQ rev (1m)11.73%
EPS NQ rev (3m)10.73%
EPS NY rev (1m)0%
EPS NY rev (3m)4.31%
Revenue NQ rev (1m)1.85%
Revenue NQ rev (3m)1.75%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.6 | ||
| Fwd PE | 9.37 | ||
| P/S | 0.8 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.16 | ||
| P/tB | 1.9 | ||
| EV/EBITDA | 10.38 |
EPS(TTM)0.88
EY5.68%
EPS(NY)1.65
Fwd EY10.67%
FCF(TTM)-1.28
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS19.43
BVpS13.32
TBVpS8.17
PEG (NY)0.15
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.25% | ||
| ROE | 6.31% | ||
| ROIC | 3.4% | ||
| ROICexc | 3.77% | ||
| ROICexgc | 5.28% | ||
| OM | 5.37% | ||
| PM | 4.33% | ||
| GM | 20.01% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.75%
GM growth 5Y8.58%
F-Score5
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.75 | ||
| Cap/Depr | 74.01% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.47 | ||
| Altman-Z | 1.74 |
F-Score5
WACC8.82%
ROIC/WACC0.6
Cap/Depr(3y)67%
Cap/Depr(5y)56.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y466.67%
EPS 3Y23.78%
EPS 5YN/A
EPS growth Q2Q3300%
EPS Next Y118.16%
EPS Next 2Y73.36%
EPS Next 3Y51.72%
EPS Next 5Y32.81%
Revenue growth 1Y31.39%
Revenue growth 3Y-5.14%
Revenue growth 5Y-0.18%
Revenue growth Q2Q26.74%
Revenue Next Year16.55%
Revenue Next 2Y13.37%
Revenue Next 3Y10.27%
Revenue Next 5Y8.52%
EBIT growth 1Y713.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year206.86%
EBIT Next 3Y60.72%
EBIT Next 5Y36.8%
FCF growth 1Y-177.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-132.33%
OCF growth 3YN/A
OCF growth 5YN/A
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Growth Stock Screener
Find more growth stocks the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA